TOFA may drive weight loss without reducing food intake
The oral compound increased energy expenditure, reduced fat mass, and improved metabolic measures in male mouse models.
-
By
-
Andrea Surnit
-
August 27, 2026
-
Clinical Scorecard: TOFA may drive weight loss without reducing food intake
At a Glance
| Category | Detail |
|---|
| Condition | Obesity and related metabolic diseases |
| Key Mechanisms | Inhibition of acetyl-CoA carboxylases 1 and 2; partial activation of PPAR alpha and delta |
| Target Population | Male mice with diet-induced obesity |
| Care Setting | Preclinical research |
Key Highlights
- TOFA reduced body weight by an average of 18% without affecting food intake.
- Improved fasting blood glucose, insulin levels, and glucose tolerance.
- Increased energy expenditure without increased physical activity.
- Reduced liver triglycerides and cholesterol levels.
- Combination therapy with TOFA and incretin analogs showed greater weight loss.
Guideline-Based Recommendations
Diagnosis
- Assessment of obesity and metabolic dysfunction in animal models.
Management
- TOFA treatment for weight loss and metabolic improvement.
Monitoring & Follow-up
- Regular evaluation of body weight, glucose levels, and lipid profiles.
Risks
- Incomplete characterization of safety profile and potential subclinical toxicity.
Patient & Prescribing Data
Male mice; further studies needed for female models.
TOFA shows potential for weight loss without reducing food intake.
Clinical Best Practices
- Consider combination therapy for enhanced weight loss and metabolic control.
- Monitor metabolic parameters during TOFA treatment.
Related Resources & Content
